Viridian Therapeutics Inc

📅 Upcoming

🕒 Recent(90d)

News

• Sling banks $123M for an experimental thyroid eye disease pill
  A confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral alternative to approved injectables like Amgen's Tepezza and Viridian's Lumvoa.
  biopharma_dive · 16d ago
• Sling catches $123M series C for thyroid eye disease pill
  Sling Therapeutics is advancing the first late-stage oral drug for thyroid eye disease that, if approved, could compete against Amgen and Viridian Therapeutics.
  biospace · 16d ago
• Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill
  Three years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer chemist has unveiled his latest venture.
  fiercebiotech · 1mo ago
• Viridian may have edge over Amgen in eye drug showdown, analysts argue
  The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.
  biopharma_dive · 3mo ago
• Ethyreal starts up with $101M and takes aim at a pair of immune diseases
  The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.
  biopharma_dive · 3mo ago
• Viridian data lift prospects for thyroid eye disease drug
  Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.
  biopharma_dive · 5mo ago
• STAT+: Are analysts too quick to gloss over Lilly’s liver case?
  Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
  stat · 5mo ago